Primary Cutaneous Lymphoma Thomas M. Habermann Mayo Clinic, Rochester, MN, USA Introduction The cutaneous T-cell disorders are a complex heterogeneous group of lymphoproliferative disorders that represent the second most common…
Small-Cell Lung Cancer Stephen V. Liu1 and Glen J. Weiss2 1University of Southern California School of Medicine, Los Angeles, CA, USA 2Cancer Treatment Centers of America, Goodyear, AZ and Translational…
Recurrent and Metastatic Non-Small-Cell Lung Cancer and Novel Targets Evan Pisick1 and Ravi Salgia2 1Cancer Treatment Centers of America, Zion, IL, USA 2The University of Chicago Medicine, Chicago, IL, USA…
Stage II and III Non-Small-Cell Lung Cancer Grzegorz Korpanty and Natasha B. Leighl Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada Case study 76.1 A 55-year-old woman, a…
Endocrine Malignancies Ann W. Gramza NIH/NCI Endocrine Oncology Branch, Bethesda, MD, USA Case study 73.1 A 48-year-old female with MEN 2A and metastatic medullary thyroid cancer (MTC) is referred for…
Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia Jerald P. Radich Fred Hutchinson Cancer Research Center, Seattle, WA, USA Tyrosine kinase therapy has revolutionized the therapy of chronic myeloid leukemia (CML)….
Prevention and Treatment of Relapse Following Hematopoietic Cell Transplantation Robert Chen, Sandra Thomas, and Stephen J. Forman City of Hope Comprehensive Cancer Center, Duarte, CA, USA Introduction Allogeneic and autologous…
Mantle Cell Lymphoma Stephen Smith1 and John Sweetenham2 1University of Washington, Seattle, WA, USA 2Huntsman Cancer Institute and University of Utah, Salt Lake City, UT, USA Case study 41.1 A…
Preparative Regimens in Allogeneic Hematopoietic Cell Transplantation for Malignant Hematological Diseases Robert J. Soiffer Dana-Farber Cancer Institute, Boston, MA, USA Traditionally, conditioning regimens prior to hematopoietic cell transplantation (HCT) were…
Radioimmunotherapy in Lymphomas Reem Karmali and Stephanie A. Gregory Rush University Medical Center/Rush University, Chicago, IL, USA Radioimmunotherapy (RIT) combines a radiation-emitting radionuclide with an anti-CD20 monoclonal antibody to treat…
